Boston Scientific (NYSE:BSX) Price Target Cut to $85.00 by Analysts at Stifel Nicolaus

Boston Scientific (NYSE:BSX) had its target price trimmed by Stifel Nicolaus from $90.00 to $85.00 in a research report released on Tuesday morning, MarketBeat.com reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Other equities analysts also recently issued reports about the stock. TD Cowen decreased their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Needham & Company LLC reissued a “buy” rating and issued a $97.00 price target on shares of Boston Scientific in a research note on Monday, March 30th. Wells Fargo & Company decreased their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Finally, The Goldman Sachs Group decreased their price target on shares of Boston Scientific from $98.00 to $93.00 and set a “buy” rating for the company in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.59.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $59.46 on Tuesday. The company has a market cap of $88.37 billion, a price-to-earnings ratio of 30.65, a price-to-earnings-growth ratio of 0.94 and a beta of 0.78. The company has a 50-day moving average price of $69.04 and a 200-day moving average price of $86.31. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific has a 12 month low of $59.38 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the prior year, the firm earned $0.70 earnings per share. Boston Scientific’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts anticipate that Boston Scientific will post 3.45 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Pinnacle Wealth Management Advisory Group LLC increased its stake in shares of Boston Scientific by 56.9% during the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 8,452 shares of the medical equipment provider’s stock valued at $530,000 after purchasing an additional 3,065 shares in the last quarter. VCI Wealth Management LLC grew its holdings in shares of Boston Scientific by 55.2% during the first quarter. VCI Wealth Management LLC now owns 24,261 shares of the medical equipment provider’s stock valued at $1,522,000 after buying an additional 8,632 shares during the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its holdings in shares of Boston Scientific by 72.7% during the first quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 38,000 shares of the medical equipment provider’s stock valued at $2,384,000 after buying an additional 16,000 shares during the last quarter. OLD National Bancorp IN grew its holdings in shares of Boston Scientific by 193.0% during the first quarter. OLD National Bancorp IN now owns 6,320 shares of the medical equipment provider’s stock valued at $397,000 after buying an additional 4,163 shares during the last quarter. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Boston Scientific during the first quarter valued at approximately $4,744,000. Institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Unusually large call-option buying: investors purchased ~60,185 call options today (about a 154% jump vs. normal), signaling speculative bullish positioning or hedging ahead of catalysts such as earnings and potential regulatory wins.
• Positive Sentiment: Analyst backing and long-term upside remain: despite recent downdraft, many firms still carry Buy/Outperform ratings and the median analyst target across recent reports sits near $100, implying material upside from current levels. Wall Street Refuses to Blink
• Neutral Sentiment: Pre-earnings positioning and scheduled Q1 report: the company reports Q1 results Wednesday (pre-market), which is driving de-risking and volatility into the print — investors are positioning for guidance and procedure trends. Q1 2026 Earnings Preview
• Neutral Sentiment: Mixed analyst tweaks: Stifel trimmed its price target (now $85) but kept a Buy rating, and Truist slightly cut its PT to $90 while remaining constructive — these are modest downward revisions but not a shift to sell consensus. Boston Scientific Stock Is Trending Today
• Negative Sentiment: Surge of securities class-action notices and filings: multiple law firms (Pomerantz, Portnoy, Faruqi, Robbins, Rosen, Bernstein Liebhard, etc.) have announced suits or investor alerts tied to a July 23, 2025–Feb 3, 2026 class period and a May 4 lead-plaintiff deadline — this increases headline/legal risk and could pressure sentiment and costs. Pomerantz Investor Alert
• Negative Sentiment: Near-term technical/valuation pressure: coverage notes and commentary report BSX near a 52-week low with YTD weakness and some analysts trimming forecasts — these factors contribute to selling momentum ahead of earnings. 52-Week Low Coverage
• Negative Sentiment: Insider selling and institutional rebalances noted in data summaries may amplify negative sentiment when combined with legal headlines and uncertain near-term procedure trends. Quiver/Market Analysis

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.